Send to:

Choose Destination
See comment in PubMed Commons below
Am J Med. 2010 Apr;123(4 Suppl):S39-46. doi: 10.1016/j.amjmed.2010.02.005.

Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.

Author information

  • 1Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.


Respiratory diseases account for approximately 10% of all hospital admissions in the United States. Pneumonia constitutes 35% of these cases, with an average length of stay (LOS) of 5.1 days. It is estimated that $8.4 billion to $10 billion of all annual US hospital expenditures are attributable to community-acquired pneumonia (CAP). As such, medical decisions, including empiric antibiotic choice, potentially exert an impact on hospital LOS and associated costs. In this review, we focus on the empiric antibiotic choices and associated costs of treatment for hospitalized patients with CAP, focusing on the use of fluoroquinolone therapy as recommended by the CAP guidelines.

Copyright 2010. Published by Elsevier Inc.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk